Skip to main content
Premium Trial:

Request an Annual Quote

Biotage Q4 Sales Increase 30 Percent; CEO Bork to Step Down

NEW YORK, Feb. 9 (GenomeWeb News) - Biotage today reported a 30-percent increase in net sales as part of its fiscal fourth-quarter earnings for 2005, and the company separately said in a statement that CEO Jeff Bork will be replaced by Torben Jörgensen, the former CEO of Affibody, effective April 27.

 

Net sales for the three months ended Oct. 1 increased 30 percent to SEK 138 million ($17.8 million) from SEK 106 million year over year.

 

R&D spending for the quarter slid to SEK 17.5 million from SEK 19.4 million in the year-ago period.

 

Fourth-quarter profit rose to SEK 2.3 million from a loss of SEK 10.6 million year over year.

 

The company had about SEK 52.8 million in cash and cash equivalents as of Dec. 31.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.